Stock analysts at JMP Securities began coverage on shares of Astria Therapeutics (NASDAQ:ATXS - Get Free Report) in a report released on Friday, Marketbeat.com reports. The firm set an "outperform" rating and a $26.00 price target on the biotechnology company's stock. JMP Securities' price target indicates a potential upside of 245.97% from the company's current price.
A number of other research firms have also recently issued reports on ATXS. HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Thursday, January 23rd. Oppenheimer boosted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an "outperform" rating in a report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $25.67.
Read Our Latest Report on Astria Therapeutics
Astria Therapeutics Stock Performance
NASDAQ:ATXS traded up $0.09 during trading hours on Friday, reaching $7.52. The company's stock had a trading volume of 198,827 shares, compared to its average volume of 299,972. Astria Therapeutics has a 1 year low of $7.16 and a 1 year high of $16.90. The firm has a 50-day simple moving average of $8.88 and a 200-day simple moving average of $10.40. The firm has a market capitalization of $424.07 million, a price-to-earnings ratio of -3.60 and a beta of 0.68.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC lifted its position in Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company's stock valued at $86,123,000 after buying an additional 1,767,714 shares during the period. Vestal Point Capital LP increased its position in Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company's stock valued at $44,040,000 after buying an additional 750,000 shares in the last quarter. Redmile Group LLC bought a new position in shares of Astria Therapeutics during the third quarter valued at $3,423,000. Cubist Systematic Strategies LLC purchased a new position in Astria Therapeutics in the second quarter worth about $2,561,000. Finally, Millennium Management LLC increased its position in shares of Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock valued at $16,763,000 after acquiring an additional 218,518 shares in the last quarter. Hedge funds and other institutional investors own 98.98% of the company's stock.
Astria Therapeutics Company Profile
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Read More
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
